Artivion Inc (AORT)

$15.06

+0.1

(+0.67%)▲

Market is closed - opens 7 PM, 22 Sep 2023

Insights on Artivion Inc

  • Increasing Revenue

    Revenue is up for the last 4 quarters, 76.83M → 89.25M (in $), with an average increase of 4.9% per quarter

  • Increasing Net Profit

    Netprofit is up for the last 2 quarters, -13.53M → -3.38M (in $), with an average increase of 300.1% per quarter

  • Vs SYK

    In the last 1 year, Stryker Corporation has given 38.3% return, outperforming this stock by 57.4%

  • Vs SYK

    In the last 3 years, Stryker Corporation has given 42.1% return, outperforming this stock by 59.0%

Performance

  • $14.65
    $15.07
    $15.06
    downward going graph

    2.72%

    Downside

    Day's Volatility :2.79%

    Upside

    0.07%

    downward going graph
  • $9.64
    $20.01
    $15.06
    downward going graph

    35.99%

    Downside

    52 Weeks Volatility :51.82%

    Upside

    24.74%

    downward going graph

Returns

PeriodArtivion IncSector (Health Care)Index (Russel 2000)
3 Months
-8.05%
-0.7%
0.0%
6 Months
26.24%
4.6%
2.4%
1 Year
-19.14%
6.7%
2.7%
3 Years
-16.89%
27.8%
18.2%

Highlights

Market Capitalization
714.5M
Book Value
$6.9
Dividend Share
0.0
Dividend Yield
0.0%
Earnings Per Share (EPS)
-0.72
PEG Ratio
181.5
Wall Street Target Price
25.3
Profit Margin
-8.66%
Operating Margin TTM
0.42%
Return On Assets TTM
0.11%
Return On Equity TTM
-10.09%
Revenue TTM
328.7M
Revenue Per Share TTM
8.15
Quarterly Revenue Growth YOY
11.1%
Gross Profit TTM
202.5M
EBITDA
23.8M
Diluted Eps TTM
-0.72
Quarterly Earnings Growth YOY
0.0
EPS Estimate Current Year
-0.58
EPS Estimate Next Year
0.08
EPS Estimate Current Quarter
-0.08
EPS Estimate Next Quarter
-0.07

Analyst Recommendation

Buy
    90%Buy
    9%Hold
    0
    0%Sell
Based on 11 Wall street analysts offering stock ratings for Artivion Inc(by analysts ranked 0 to 5 stars)
Based on 11 analyst
  • Current
  • 1M Ago
  • 3M Ago
Buy
10
10
10
Hold
1
1
2
Sell
00
00
00

Analyst Forecast

What analysts predicted

Upside of 67.99%

Current $15.06
Target $25.30

Company Financials

FY17Y/Y Change
Revenue
189.7M
↑ 5.17%
Net Income
3.7M
↓ 65.63%
Net Profit Margin
1.95%
↓ 4.03%
FY18Y/Y Change
Revenue
262.8M
↑ 38.55%
Net Income
-2.8M
↓ 176.67%
Net Profit Margin
-1.08%
↓ 3.03%
FY19Y/Y Change
Revenue
276.2M
↑ 5.09%
Net Income
1.7M
↓ 160.56%
Net Profit Margin
0.62%
↑ 1.7%
FY20Y/Y Change
Revenue
253.2M
↓ 8.32%
Net Income
-16.7M
↓ 1069.88%
Net Profit Margin
-6.59%
↓ 7.21%
FY21Y/Y Change
Revenue
298.8M
↑ 18.01%
Net Income
-14.8M
↓ 11.08%
Net Profit Margin
-4.96%
↑ 1.63%
FY22Y/Y Change
Revenue
313.8M
↑ 5.0%
Net Income
-19.2M
↑ 29.38%
Net Profit Margin
-6.12%
↓ 1.16%
Q1 FY22Q/Q Change
Revenue
77.2M
↓ 2.75%
Net Income
-3.4M
↓ 83.14%
Net Profit Margin
-4.39%
↑ 20.93%
Q2 FY22Q/Q Change
Revenue
80.3M
↑ 4.05%
Net Income
-4.3M
↑ 25.67%
Net Profit Margin
-5.3%
↓ 0.91%
Q3 FY22Q/Q Change
Revenue
76.8M
↓ 4.36%
Net Income
-13.7M
↑ 221.98%
Net Profit Margin
-17.85%
↓ 12.55%
Q4 FY22Q/Q Change
Revenue
79.4M
↑ 3.33%
Net Income
2.2M
↓ 115.82%
Net Profit Margin
2.73%
↑ 20.58%
Q1 FY23Q/Q Change
Revenue
83.2M
↑ 4.83%
Net Income
-13.5M
↓ 723.88%
Net Profit Margin
-16.26%
↓ 18.99%
Q2 FY23Q/Q Change
Revenue
89.3M
↑ 7.24%
Net Income
-3.4M
↓ 75.01%
Net Profit Margin
-3.79%
↑ 12.47%
FY17Y/Y Change
Total Assets
589.7M
↑ 86.53%
Total Liabilities
312.6M
↑ 191.75%
FY18Y/Y Change
Total Assets
571.1M
↓ 3.15%
Total Liabilities
296.0M
↓ 5.31%
FY19Y/Y Change
Total Assets
605.7M
↑ 6.05%
Total Liabilities
320.0M
↑ 8.09%
FY20Y/Y Change
Total Assets
789.4M
↑ 30.34%
Total Liabilities
460.7M
↑ 43.98%
FY21Y/Y Change
Total Assets
793.1M
↑ 0.46%
Total Liabilities
492.3M
↑ 6.87%
FY22Y/Y Change
Total Assets
762.8M
↓ 3.81%
Total Liabilities
478.5M
↓ 2.81%
Q1 FY22Q/Q Change
Total Assets
781.9M
↓ 1.41%
Total Liabilities
484.4M
↓ 1.62%
Q2 FY22Q/Q Change
Total Assets
764.9M
↓ 2.17%
Total Liabilities
483.4M
↓ 0.21%
Q3 FY22Q/Q Change
Total Assets
742.7M
↓ 2.89%
Total Liabilities
487.6M
↑ 0.88%
Q4 FY22Q/Q Change
Total Assets
762.8M
↑ 2.7%
Total Liabilities
478.5M
↓ 1.88%
Q1 FY23Q/Q Change
Total Assets
757.1M
↓ 0.75%
Total Liabilities
477.2M
↓ 0.27%
Q2 FY23Q/Q Change
Total Assets
777.9M
↑ 2.75%
Total Liabilities
495.4M
↑ 3.81%
FY17Y/Y Change
Operating Cash Flow
10.8M
↓ 45.22%
Investing Cash Flow
-171.0M
-
Financing Cash Flow
143.2M
↑ 95.08%
FY18Y/Y Change
Operating Cash Flow
9.9M
↓ 8.53%
Investing Cash Flow
-6.7M
↓ 96.07%
Financing Cash Flow
-2.6M
↓ 101.79%
FY19Y/Y Change
Operating Cash Flow
15.8M
↑ 60.18%
Investing Cash Flow
-23.9M
↑ 256.56%
Financing Cash Flow
-1.5M
↓ 41.73%
FY20Y/Y Change
Operating Cash Flow
12.4M
↓ 21.85%
Investing Cash Flow
-73.1M
↑ 205.43%
Financing Cash Flow
93.6M
↓ 6369.79%
FY21Y/Y Change
Operating Cash Flow
-2.6M
↓ 120.9%
Investing Cash Flow
5.7M
↓ 107.74%
Financing Cash Flow
-12.2M
↓ 113.06%
Q1 FY22Q/Q Change
Operating Cash Flow
-598.0K
↓ 183.52%
Investing Cash Flow
-2.7M
↓ 3.7%
Financing Cash Flow
-235.0K
↓ 97.33%
Q2 FY22Q/Q Change
Operating Cash Flow
-8.3M
↑ 1290.3%
Investing Cash Flow
-2.3M
↓ 15.58%
Financing Cash Flow
-797.0K
↑ 239.15%
Q3 FY22Q/Q Change
Operating Cash Flow
4.0M
↓ 147.82%
Investing Cash Flow
-3.1M
↑ 33.55%
Financing Cash Flow
252.0K
↓ 131.62%

Peers

Company Name1 Month6 Month1 Year3 Years5 Years
Artivion Inc
Artivion Inc
-10.31%
26.24%
-19.14%
-16.89%
-57.68%
Stryker Corporation
Stryker Corporation
4.9%
6.11%
38.34%
42.41%
65.6%
Boston Scientific Corp.
Boston Scientific Corp.
7.06%
12.27%
37.66%
40.16%
40.89%
Edwards Lifesciences Corp.
Edwards Lifesciences Corp.
-5.29%
-9.39%
-14.52%
-8.55%
30.45%
Abbott Laboratories
Abbott Laboratories
-4.63%
3.53%
-0.78%
-4.31%
40.37%
Medtronic Plc
Medtronic Plc
-2.68%
1.93%
-2.49%
-22.25%
-17.58%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
Artivion Inc
Artivion Inc
NA
NA
181.5
-0.58
-0.1
0.0
0.0
6.9
Stryker Corporation
Stryker Corporation
40.82
40.82
2.85
10.36
0.16
0.06
0.01
45.71
Boston Scientific Corp.
Boston Scientific Corp.
88.69
88.69
2.53
1.99
0.05
0.04
0.0
12.46
Edwards Lifesciences Corp.
Edwards Lifesciences Corp.
31.84
31.84
3.07
2.55
0.22
0.12
0.0
10.49
Abbott Laboratories
Abbott Laboratories
34.23
34.23
18.76
4.39
0.14
0.06
0.02
21.42
Medtronic Plc
Medtronic Plc
30.07
30.07
3.04
5.28
0.07
0.04
0.03
38.47
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
Artivion Inc
Artivion Inc
Buy
$714.5M
-57.68%
NA
-8.66%
Stryker Corporation
Stryker Corporation
Buy
$109.7B
65.6%
40.82
13.92%
Boston Scientific Corp.
Boston Scientific Corp.
Buy
$79.2B
40.89%
88.69
6.81%
Edwards Lifesciences Corp.
Edwards Lifesciences Corp.
Buy
$43.7B
30.45%
31.84
24.56%
Abbott Laboratories
Abbott Laboratories
Buy
$174.0B
40.37%
34.23
12.83%
Medtronic Plc
Medtronic Plc
Buy
$109.9B
-17.58%
30.07
11.47%

Institutional Holdings

  • BlackRock Inc

    17.26%

  • Macquarie Group Ltd

    6.75%

  • Vanguard Group Inc

    6.68%

  • Wellington Management Company LLP

    6.29%

  • Morgan Stanley - Brokerage Accounts

    5.47%

  • Juniper Investment Co, LLC

    5.11%

Corporate Announcements

  • Artivion Inc Earnings

    Artivion Inc’s price-to-earnings ratio stands at None

    Read More

Company Information

cryolife, headquartered in georgia, is a leader in the processing and distribution of human tissues for use in cardiac and vascular surgeries. cryolife using its proprietary synergraft® technology processes the cryovalve® sg pulmonary heart valve and cryopatch® sg pulmonary cardiac patch. cryolife’s bioglue® surgical adhesive is approved in the u.s. for use as an adjunct to sutures and staples to help control bleeding, ce marked in the european community, approved in canada and australia for use in soft tissue repair, and in japan for use in the repair of aortic dissections. cryolife’s cardiogenesis specializes in the treatment of severe angina using a laser console system and fiber-optic handpieces to perform a surgical procedure known as transmyocardial revascularization (tmr). cryolife markets the hero® graft, which provides vascular access for hemodialysis patients. cryolife distributes perclot®, an absorbable powdered hemostat, in international markets. cryolife’s biofoam® surgica

Organization
Artivion Inc
Employees
1300
CEO
Mr. James Patrick Mackin
Industry
Healthcare

Discover More

FAQs